-
1 Comment
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, PMV Pharmaceuticals, Inc gets an overall score of 1/5.
ISIN | US69353Y1038 |
---|---|
Sector | Healthcare |
Industry | Biotechnology |
Exchange | NASDAQ |
CurrencyCode | USD |
Target Price | 5.8 |
---|---|
Beta | 1.49 |
Market Cap | 56M |
PE Ratio | None |
Dividend Yield | None |
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is rezatapopt, an orally available small molecule that potently and selectively correct p53 misfolding caused by p53 mutation, Y220C, while sparing wild-type p53. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for PMVP using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025